Protalix BioTherapeutics (PLX) Accumulated Depreciation & Amortization (2010 - 2025)

Protalix BioTherapeutics has reported Accumulated Depreciation & Amortization for 16 years, with the latest figure at $37.0 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 3.66% year-over-year to $37.0 million; the trailing twelve-month figure through Dec 2025 stood at $37.0 million (up 3.66% YoY), and the FY2025 full-year result was $37.0 million, up 3.66% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $37.0 million, up from $35.7 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $37.0 million in Q4 2025, with the low at $32.8 million in Q4 2021.
• Average Accumulated Depreciation & Amortization over 5 years is $34.8 million, with a median of $34.7 million recorded in 2023.
• Year-over-year, Accumulated Depreciation & Amortization gained 2.6% in 2021 and advanced 3.66% in 2025.
• Tracing PLX's Accumulated Depreciation & Amortization over 5 years: stood at $32.8 million in 2021, then rose by 2.85% to $33.7 million in 2022, then climbed by 2.97% to $34.7 million in 2023, then gained by 3.03% to $35.7 million in 2024, then gained by 3.66% to $37.0 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $37.0 million (Q4 2025), $35.7 million (Q4 2024), and $34.7 million (Q4 2023), per Business Quant data.

Peer Comparison